You may have heard that MPNRF, along with fellow MPN advocates, is holding an externally-led Patient Focused Drug Development meeting with the FDA this September. If you are… Read More »LET THE FDA KNOW ABOUT YOUR EXPERIENCE LIVING WITH PV, ET OR MF!
BLOOD ARTICLE DISCUSSES EPIGENETIC CHANGES IN MYELOFIBROSIS FOLLOWING DISCONTINUATION OF RUXOLITINIB
The MPN community is discussing the article by MPN researchers from MD Anderson – Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation – a retrospective study… Read More »BLOOD ARTICLE DISCUSSES EPIGENETIC CHANGES IN MYELOFIBROSIS FOLLOWING DISCONTINUATION OF RUXOLITINIB
Parterships are Important. They bring people together in pursuit of a common cause and put many minds to work on a problem, increasing the likelihood… Read More »THE IMPORTANCE OF PARTNERSHIPS IN THE MPN COMMUNITY
Even though MPN patients who have a rare disease many may have never heard of “Rare Disease Day” and know next to nothing about the… Read More »FEBRUARY 29TH IS RARE DISEASE DAY: 4 REASONS YOU SHOULD CARE
The Centers for Medicare & Medicaid Services’ Coverage and Analysis Group released a proposed decision memo Thursday on modifications to the National Coverage Determination for… Read More »UPDATE ON MEDICARE COVERAGE DECISION FOR STEM CELL TRANSPLANT IN MYELOFIBROSIS